|
|||||
|
|
Tuberculosis research update |
|
| Authors: | W A Hanekom S D Lawn K Dheda A Whitelaw |
| Affiliation: | 1. South African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town, South Africa;2. Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa;3. Clinical Research Unit, London School of Hygiene & Tropical Medicine, London, UK;4. Lung Infection and Immunity Unit, University of Cape Town, Cape Town, South Africa;5. Centre for Infectious Diseases and International Health, University College London, London, UK;6. Division of Medical Microbiology, University of Cape Town, Cape Town, South Africa;7. National Health Laboratory Service, Cape Town, South Africa |
| Abstract: | Tuberculosis (TB) remains a major challenge to global public health in the 21st century. In 2007, there were an estimated 9.27 million new cases and 1.3 million deaths among HIV‐negative patients with TB. The HIV‐associated TB epidemic, drug‐resistant disease, the need for better diagnostic assays and the limited efficacy of Bacille Calmette–Guerin vaccination are four important obstacles to further progress in global TB control. In this brief review, we provide a focused update on these four key areas of TB research. |
| Keywords: | tuberculosis vaccine drug resistance HIV diagnosis tuberculose vaccin ré sistance aux mé dicaments VIH diagnostic tuberculosis vacuna resistencia a medicamentos VIH diagnó stico |
